What is Tango Therapeutics's R&D?

Tango Therapeutics (TNGX) reported R&D of $33.53M in Q1 2026.

How has Tango Therapeutics's R&D changed year-over-year?

Tango Therapeutics's R&D decreased by 8.0% year-over-year, from $36.44M to $33.53M.

What is the long-term trend for Tango Therapeutics's R&D?

Over 4 years (2021 to 2025), Tango Therapeutics's R&D has grown at a 14.2% compound annual growth rate (CAGR), from $77.64M to $132.17M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Tango Therapeutics TNGX R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

AmgenAMGN

$1.72B+15.7%

ExelixisEXEL

$199.92M-5.8%

Cogent Biosciences, Inc.COGT

$75.37M+19.6%

CG OncologyCGON

$43.73M+59.2%

Lantheus HoldingsLNTH

$39.38M+8.4%

Segments

By segment

See full

Personnel-Related Expenses-RD$12.93M-6.6%

Vopimetostat Direct Program Expenses-RD$9.33M+70.9%

Facilities And Other Related Expenses-RD$4.34M-20.6%

TNG456Direct Program Expenses-RD$2.06M+55.8%

TNG260Direct Program Expenses-RD$2.01M+16.1%

Discovery Direct Program Expenses-RD$1.87M-60.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's R&D?: Tango Therapeutics (TNGX) reported R&D of $33.53M in Q1 2026.
How has Tango Therapeutics's R&D changed year-over-year?: Tango Therapeutics's R&D decreased by 8.0% year-over-year, from $36.44M to $33.53M.
What is the long-term trend for Tango Therapeutics's R&D?: Over 4 years (2021 to 2025), Tango Therapeutics's R&D has grown at a 14.2% compound annual growth rate (CAGR), from $77.64M to $132.17M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.